Risk of Celiac Disease Autoimmunity is Modified by Non-HLA Genetic Markers During the First Year of Clinical Type 1 Diabetes 

Authors

  • Emma H. Adlercreutz Department of Clinical Sciences, Diabetes and Celiac Disease Unit, Lund University, SE-20502 Malmo, Sweden
  • Dorthe Hansen Department of Paediatrics, Odense University Hospital, Sdr. Boulevard 29, 5000 Odense C, Denmark
  • Henrik B. Mortensen Department of Paediatrics, Herlev Hospital, Herlev Ringvej 75, 2730 Herlev, Denmark and Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
  • Åke Lernmark Department of Clinical Sciences, Diabetes and Celiac Disease Unit, Lund University, SE-20502 Malmo, Sweden
  • Karsten Buschard The Bartholin Institute, Rigshospitalet, Blegdamsvej 9, 2100 Copenhagen, Denmark
  • Daniel Agardh Department of Clinical Sciences, Diabetes and Celiac Disease Unit, Lund University, SE-20502 Malmo, Sweden
  • Jannet Svensson Department of Paediatrics, Herlev Hospital, Herlev Ringvej 75, 2730 Herlev, Denmark and Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark

DOI:

https://doi.org/10.12970/2310-9971.2014.02.02.4

Keywords:

 Autoimmunity, celiac disease, children, HLA, genes, type 1 diabetes

Abstract

 Aims: This study plotted the prevalence of celiac disease associated antibodies in relation to demographic patterns, genetic and metabolic markers during the first year after diagnosis in a multinational cohort of children with T1D. Material and Methods: Sera from a total of 261 children (128 males, 133 females) (0.5-16.3 years) with T1D recruited at 18 European centers were screened at 1, 6 and 12 months after diagnosis, using a combined ELISA measuring both IgA and IgG antibodies against deamidated gliadin peptide and tissue transglutaminase (IgAG-DGP/tTG) and a radioligand binding assays measuring IgG-tTG. Children positive in both assays in two consecutive samples were defined as having celiac disease autoimmunity (CDA). Associations between CDA and genotypes of HLA, IL18 rap, CCR 5, PTPN2 and correlations with islet autoantibodies (ICA, GADA, IA2 and IA) and HbA1C and C-peptide were performed. Results: At the one, six and twelve month visit after T1D diagnosis, the prevalence of IgAG-DGP/tTG across all sites were 24/238 (10.1%), 18/224 (8.0%) and 25/218 (11.5%), respectively, and 11/238 (4.6%) were confirmed positive for IgG-tTG and defined as having CDA. A subpopulation of T1D children with high levels of IgAG-DGP/tTG were defined and associated with the genotype AA of IL18RAP. Conclusions: In our multinational cohort of children with T1D, approximately 5% were affected by CDA during first year after diagnosis of T1D. Independent of country of residence, a subpopulation being homozygote for IL18RAP were found with high levels of IgAG-DGP/tTG, indicating that non-HLA-DQ2/DQ8 genetic markers may modulate the risk for developing CDA in T1D. 

References


[1] Karell K, Louka AS, Moodie SJ, et al. HLA types in celiac disease patients not carrying the DQA1*05-DQB1*02 (DQ2) heterodimer: results from the European Genetics Cluster on Celiac Disease. Hum Immunol 2003; 64: 469-77. http://dx.doi.org/S0198885903000272
[2] Noble JA, Valdes AM, Cook M, Klitz W, Thomson G, Erlich HA. The role of HLA class II genes in insulin-dependent diabetes mellitus: molecular analysis of 180 Caucasian, multiplex families. Am J Hum Genet 1996; 59: 1134-48.
[3] Ploski R, Ek J, Thorsby E, Sollid LM. On the HLA-DQ (alpha 1*0501, beta 1*0201)-associated susceptibility in celiac disease: a possible gene dosage effect of DQB1*0201. Tissue Antigens 1993; 41: 173-7. http://dx.doi.org/10.1111/j.1399-0039.1993.tb01998.x
[4] Bao F, Yu L, Babu S, et al. One third of HLA DQ2 homozygous patients with type 1 diabetes express celiac disease-associated transglutaminase autoantibodies. J Autoimmun 1999; 13: 143-8. http://dx.doi.org/10.1006/jaut.1999.0303
[5] Trynka G, Hunt KA, Bockett NA, et al. Dense genotyping identifies and localizes multiple common and rare variant association signals in celiac disease. Nat Genet 2011; 43: 1193-201. http://dx.doi.org/10.1038/ng.998
[6] Hummel M, Bonifacio E, Stern M, Dittler J, Schimmel A, Ziegler AG. Development of celiac disease-associatedantibodies in offspring of parents with type I diabetes. Diabetologia 2000; 43: 1005-11. http://dx.doi.org/10.1007/s001250051483
[7] Waisbourd-Zinman O, Hojsak I, Rosenbach Y, et al. Spontaneous normalization of anti-tissue transglutaminase antibody levels is common in children with type 1 diabetes mellitus. Dig Dis Sci 2012; 57: 1314-20. http://dx.doi.org/10.1007/s10620-011-2016-0
[8] Mortensen HB, Hougaard P. Comparison of metabolic control in a cross-sectional study of 2,873 children and adolescents with IDDM from 18 countries. The Hvidore Study Group on Childhood Diabetes. Diabetes Care 1997; 20: 714-20. http://dx.doi.org/10.2337/diacare.20.5.714
[9] Mortensen HB, Swift PG, Holl RW, et al. Multinational study in children and adolescents with newly diagnosed type 1 diabetes: association of age, ketoacidosis, HLA status, and autoantibodies on residual beta-cell function and glycemic control 12 months after diagnosis. Pediatr Diabetes 2010; 11: 218-26. http://dx.doi.org/10.1111/j.1399-5448.2009.00566.x
[10] Agardh D. Antibodies against synthetic deamidated gliadin peptides and tissue transglutaminase for the identification of childhood celiac disease. Clin Gastroenterol Hepatol 2007; 5: 1276-81. http://dx.doi.org/S1542-3565(07)00547-2
[11] Grubin CE, Daniels T, Toivola B, et al. A novel radioligand binding assay to determine diagnostic accuracy of isoformspecific glutamic acid decarboxylase antibodies in childhood IDDM. Diabetologia 1994; 37: 344-50. http://dx.doi.org/10.1007/BF00408469
[12] Falorni A, Ortqvist E, Persson B, Lernmark A. Radioimmunoassays for glutamic acid decarboxylase (GAD65) and GAD65 autoantibodies using 35S or 3H recombinant human ligands. J Immunol Methods 1995; 186: 89-99. http://dx.doi.org/0022175995001392
[13] Ljungberg UK, Jansson B, Niss U, Nilsson R, Sandberg BE, Nilsson B. The interaction between different domains of staphylococcal protein A and human polyclonal IgG, IgA, IgM and F(ab')2: separation of affinity from specificity. Mol Immunol 1993; 30: 1279-85. http://dx.doi.org/10.1016/0161-5890(93)90044-C
[14] Agardh D, Dahlbom I, Daniels T, et al. Autoantibodies against soluble and immobilized human recombinant tissue transglutaminase in children with celiac disease. J Pediatr Gastroenterol Nutr 2005; 41: 322-7. http://dx.doi.org/10.1097/01.mpg.0000174845.90668.fa
[15] Bazzigaluppi E, Lampasona V, Barera G, et al. Comparison of tissue transglutaminase-specific antibody assays with established antibody measurements for coeliac disease. J Autoimmun 1999; 12: 51-6. http://dx.doi.org/10.1006/jaut.1998.0253
[16] Porksen S, Nielsen LB, Kaas A, et al. Meal-stimulated glucagon release is associated with postprandial blood glucose level and does not interfere with glycemic control in children and adolescents with new-onset type 1 diabetes. J Clin Endocrinol Metab 2007; 92: 2910-6. http://dx.doi.org/10.1210/jc.2007-0244
[17] Simell S, Kupila A, Hoppu S, et al. Natural history of transglutaminase autoantibodies and mucosal changes in children carrying HLA-conferred celiac disease susceptibility. Scand J Gastroenterol 2005; 40: 1182-91. http://dx.doi.org/10.1080/00365520510024034
[18] Levy-Shraga Y, Lerner-Geva L, Boyko V, et al. Type 1 diabetes in pre-school children--long-term metabolic control, associated autoimmunity and complications. Diabet Med 2012; 29: 1291-6. http://dx.doi.org/10.1111/j.1464-5491.2012.03682.x
[19] Shanahan F, McKenna R, McCarthy CF, Drury MI. Coeliac disease and diabetes mellitus: a study of 24 patients with HLA typing. Q J Med 1982; 51: 329-35.
[20] Lorini R, Scaramuzza A, Vitali L, et al. Clinical aspects of coeliac disease in children with insulin-dependent diabetes mellitus. J Pediatr Endocrinol Metab 1996; 9 (Suppl 1): 101- 11. http://dx.doi.org/10.1515/JPEM.1996.9.S1.101
[21] Leeds JS, Hopper AD, Hadjivassiliou M, Tesfaye S, Sanders DS. Potential coeliac disease in type 1 diabetes mellitus: does a positive antibody lead to increased complications? Nutr Metab Cardiovasc Dis 2014; 24: 378-83. http://dx.doi.org/10.1016/j.numecd.2013.09.005
[22] Moon MJ, Kim HY, Park S, et al. Insulin contributes to finetuning of the pancreatic beta-cell response to glucagon-like peptide-1. Mol Cells 2011; 32: 389-95. http://dx.doi.org/10.1007/s10059-011-0157-9
[23] Schmidt WE, Siegel EG, Creutzfeldt W. Glucagon-like peptide-1 but not glucagon-like peptide-2 stimulates insulin release from isolated rat pancreatic islets. Diabetologia 1985; 28: 704-7. http://dx.doi.org/10.1007/BF00291980
[24] Vella A, Rizza RA. Extrapancreatic effects of GIP and GLP-1. Horm Metab Res 2004; 36: 830-6. http://dx.doi.org/10.1055/s-2004-82617
[25] Caddy GR, Ardill JE, Fillmore D, et al. Plasma concentrations of glucagon-like peptide-2 in adult patients with treated and untreated coeliac disease. Eur J Gastroenterol Hepatol 2006; 18: 195-202. http://dx.doi.org/10.1097/00042737-200602000-00013
[26] Smyth DJ, Plagnol V, Walker NM, et al. Shared and distinct genetic variants in type 1 diabetes and celiac disease. N Engl J Med 2008; 359: 2767-77. http://dx.doi.org/NEJMoa0807917
[27] Mahmud FH, Murray JA, Kudva YC, et al. Celiac disease in type 1 diabetes mellitus in a North American community: prevalence, serologic screening, and clinical features. Mayo Clin Proc 2005; 80: 1429-34. http://dx.doi.org/S0025-6196(11)61436-5
[28] Li M, Yu L, Tiberti C, et al. A report on the International Transglutaminase Autoantibody Workshop for Celiac Disease. Am J Gastroenterol 2009; 104: 154-63. http://dx.doi.org/10.1038/ajg.2008.8

Downloads

Published

2014-04-05

Issue

Vol. 2 No. 1 (2014)

Section

Articles